Benzinga - by Benzinga Insights, Benzinga Staff Writer.
HENRY FUCHS, President at Biomarin Pharmaceutical (NASDAQ:BMRN), reported an insider sell on March 7, according to a new SEC filing.
What Happened: FUCHS's decision to sell 35,341 shares of Biomarin Pharmaceutical was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The total value of the sale is $3,010,395.
In the Friday's morning session, Biomarin Pharmaceutical's shares are currently trading at $86.05, experiencing a up of 0.19%.
Delving into Biomarin Pharmaceutical's Background BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Biomarin Pharmaceutical: Delving into Financials Revenue Growth: Biomarin Pharmaceutical's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 20.22%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Navigating Financial Profits:
- Gross Margin: The company shows a low gross margin of 79.03%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
- Earnings per Share (EPS): Biomarin Pharmaceutical's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.11.
Evaluating Valuation:
- Price to Earnings (P/E) Ratio: Biomarin Pharmaceutical's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 98.72.
- Price to Sales (P/S) Ratio: With a P/S ratio of 6.8 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Boasting an EV/EBITDA ratio of 52.4, Biomarin Pharmaceutical demonstrates a robust market valuation, outperforming industry benchmarks.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Unmasking the Significance of Insider Transactions Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
Exploring Key Transaction Codes In the domain of transactions, investors frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Biomarin Pharmaceutical's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.